Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism

被引:104
|
作者
Ding, WG
Renstrom, E
Rorsman, P
Buschard, K
Gromada, J
机构
[1] NOVO NORDISK AS,DEPT ISLET CELL PHYSIOL,DK-2100 COPENHAGEN,DENMARK
[2] KOMMUNE HOSP COPENHAGEN,BARTHOLIN INST,COPENHAGEN,DENMARK
关键词
D O I
10.2337/diabetes.46.5.792
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
High-resolution capacitance measurements were used to explore the effects of the gut hormones GLP-I(7-36) amide [glucagon-Like peptide I(7-36) amide] and GIP (glucose-dependent insulinotropic polypeptide) on Ca2+-dependent exocytosis in glucagon-secreting rat pancreatic alpha-cells, Both peptides produced a greater than threefold potentiation of secretion evoked by voltage-clamp depolarizations, an effect that was associated with an similar to 35% increase of the Ca2+ current. The stimulatory actions of GLP-I(7-36) amide and GIP were mimicked by forskolin and antagonized by the protein kinase A (PKA)inhibitor Rp-8-Br-cAMPS. The islet hormone somatostatin inhibited the stimulatory action of GLP-I(7-36) amide and GIP via a cyclic AMP-independent mechanism, whereas insulin had no effect on exocytosis. These data suggest that the alpha-cells are equipped with receptors for GLP-I and GIP and that these peptides, in addition to their well-established insulinotropic capacity, also stimulate glucagon secretion. We propose that the reported inhibitory action of GLP-I on glucagon secretion is accounted for by a paracrine mechanism (e.g., mediated by stimulated release of somatostatin that in turn suppresses exocytosis in the alpha-cell).
引用
收藏
页码:792 / 800
页数:9
相关论文
共 50 条
  • [21] Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus
    Wong, Elaine
    Cope, Rebecca
    Dima, Lorena
    Nguyen, Timothy
    AMERICAN JOURNAL OF THERAPEUTICS, 2023, 30 (01) : E26 - E35
  • [22] Targeting central pathway of Glucose-Dependent Insulinotropic Polypeptide, Glucagon and Glucagon-like Peptide-1 for metabolic regulation in obesity and type 2 diabetes
    Xu, Zhimin
    Wen, Song
    Dong, Meiyuan
    Zhou, Ligang
    DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 1660 - 1675
  • [23] A Case of Severe Cholestatic Hepatitis Induced by a Novel Dual Agonist of Glucagon-like Peptide-1 and Glucose-dependent Insulinotropic Polypeptide Receptors
    Jiang, Junmin
    Shi, Meifeng
    Wu, Shuduo
    Cao, Minling
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2024, 12 (11) : 949 - 954
  • [24] A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide-expressing cells in the hypothalamus
    Smith, Christopher
    Patterson-Cross, Ryan
    Woodward, Orla
    Lewis, Jo
    Chiarugi, Davide
    Merkle, Florian
    Gribble, Fiona
    Reimann, Frank
    Adriaenssens, Alice
    APPETITE, 2022, 174
  • [25] Potential of a glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes
    Araki, Eiichi
    Sakaguchi, Masaji
    Fukuda, Kazuki
    Kondo, Tatsuya
    JOURNAL OF DIABETES INVESTIGATION, 2022,
  • [26] The incretin hormone receptors for glucose-dependent insulinotropic peptide and glucagon-like peptide 2 are expressed in both osteoblast and osteoclast-like cells.
    Kang, B.
    Zhong, Q.
    Sridhar, S.
    Insogna, K.
    Bollag, W.
    Bollag, R. J.
    Curl, W.
    Isales, C. M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S339 - S339
  • [27] Tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in the management of type 2 diabetes: the SURPASS trials
    Aberle, Jens
    Forst, Thomas
    Heitmann, Elke
    Goergens, Sven W.
    Seufert, Jochen
    DIABETOLOGIE UND STOFFWECHSEL, 2023, 18 (06) : 461 - 474
  • [28] Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight
    Schou, JH
    Pilgaard, K
    Vilsboll, T
    Jensen, CB
    Deacon, CF
    Holst, JJ
    Volund, A
    Madsbad, S
    Vaag, AA
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (08): : 4912 - 4919
  • [29] Colesevelam HCl improves glucose metabolism and increases plasma glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide concentrations in subjects with type 2 diabetes
    Beysen, C.
    Deines, K. C.
    Tsang, E. L.
    Murphy, E. J.
    Chan, M.
    Edmonds, J. M.
    Neese, R. A.
    Hellerstein, M. K.
    DIABETOLOGIA, 2009, 52 : S77 - S77
  • [30] Insulin, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and insulin-like growth factor I as putative mediators of the hypolipidemic effect of oligofructose in rats
    Kok, NN
    Morgan, LM
    Williams, CM
    Roberfroid, MB
    Thissen, JP
    Delzenne, NM
    JOURNAL OF NUTRITION, 1998, 128 (07): : 1099 - 1103